Parkinson’s UK is highlighting the efforts of those working to improve the representation of people with African and Caribbean lineage in Parkinson’s disease research as part of Black History Month, observed every October in the United Kingdom. The nonprofit organization is also calling attention to a free online…
News
Treatment with cianidanol, a plant molecule that can activate a specific estrogen receptor in the brain, showed neuroprotective potential in cell and animal models of Parkinson’s disease, a study reports. “The identification of cianidanol as a selective estrogen receptor beta agonist and evaluation of its neuroprotective…
A new set of guidelines, developed by a team of scientists in China, outline ways healthcare professionals can help people with Parkinson’s disease to deal with constipation — and the focus is on  emotional support to help patients, and emphasizing the importance of open dialogue. The study, “Breaking…
It may be possible to spot telltale signs of Parkinson’s disease on positron emission tomography (PET) scans as early as 20 to 30 years before symptoms become evident and a definite clinical diagnosis can be made, a study suggests. PET scans that track a protein called vesicular…
The use of over-the-counter pain medicines like ibuprofen and aspirin do not appear to influence the clinical progression of Parkinson’s disease, a recent study reveals. The study, “Non-steroidal anti-inflammatory drug use and markers of Parkinson’s disease progression: A retrospective cohort study,” was published in the Journal…
Botulinum toxin was found to be relatively safe and effective for treating excessive drooling in people with Parkinson’s disease, according to a recent systematic review and meta-analysis of previous clinical trials. While side effects usually were mild, the researchers believe larger and longer studies are needed to establish the…
Cure Parkinson’s is funding preclinical research that intends to provide the evidence needed to determine whether three existing compounds are ready to move forward into clinical trials in people with Parkinson’s disease, the U.K. charity announced. The funding comes as part of the recently launched Pipeline Research…
A once-daily 200 mg dose of Inhibikase Therapeutics’ risvodetinib — an oral medication previously called IkT-148009, now undergoing Phase 2 clinical testing — is safe, and can improve motor function and ease activities of daily living in people with previously untreated Parkinson’s disease. That’s according to now…
A first healthy volunteer has been dosed in a Phase 1 clinical trial assessing the safety and tolerability of HL192, an investigational therapy for Parkinson’s disease. The treatment, given orally, is designed to activate Nurr1, a key protein that regulates the development and maintenance of dopaminergic neurons. These nerve…
The American Parkinson’s Disease Association (APDA) received three MM+M awards, including the titanium Best in Show, for its ParkinSex guide to help people with Parkinson’s disease and their partners retain sexual intimacy. Now in its 20th year, the MM+M Awards recognize creativity and effectiveness in…
Recent Posts
- Amprion working to expand access globally to alpha-synuclein protein test
- When saying no feels like the hardest part of Parkinson’s caregiving
- Researchers ID compound that may slow Parkinson’s progression
- ‘If it ain’t broke, break it’: Lessons for Parkinson’s caregivers
- New campaign aims to boost early recognition of Parkinson’s symptoms